What does Aviadobio do?

AviadoBio is a clinical-stage biotechnology company based in London, UK, with operations in New Jersey, US. Founded in 2019, the company specializes in developing gene therapies for neurodegenerative diseases, particularly frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). AviadoBio utilizes proprietary platforms to ensure precise delivery of therapies to the brain, spinal cord, and retina, aiming to halt or reverse neurodegeneration. The company translates pioneering research from King’s College London and the UK Dementia Research Institute into innovative treatments. Led by CEO Lisa Deschamps, AviadoBio focuses on overcoming delivery challenges in gene therapy through a neuroanatomy-led approach. Their pipeline includes gene therapies that leverage AAV vectors and advanced delivery technologies to address the genetic causes of FTD and ALS. The team comprises experts in gene therapy and clinical research, dedicated to advancing potential therapies for previously untreatable neurological diseases.